Azithromycin improves lung function in patients with post-lung transplant bronchiolitis obliterans syndrome: A meta-analysis

Clinical Transplantation

Volumn 28, Issue 8, 2014, Pages 906-910

  Kingah, Pascal L ^a   Muma, Gilbert ^b   Soubani, Ayman ^a  

^a HARPER UNIVERSITY HOSPITAL   (United States)

^b ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

Azithromycin; Bronchiolitis obliterans; Chronic rejection; Lung function; Lung transplant

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN;

ADVERSE EFFECTS; BRONCHIOLITIS OBLITERANS; HUMAN; LUNG FUNCTION TEST; LUNG TRANSPLANTATION; META ANALYSIS; PROGNOSIS; SYNDROME;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BRONCHIOLITIS OBLITERANS; HUMANS; LUNG TRANSPLANTATION; PROGNOSIS; RESPIRATORY FUNCTION TESTS; SYNDROME;

EID: 84905590373     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12401     Document Type: Article

References (26)

1. Estenne M, Maurer JR, Boehler A et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002: 21: 297.
2. Bankier AA, Van Muylen A, Knoop C, Estenne M, Gevenios PA. Bronchiolitis obliterans syndrome in heart-lung transplant recipients: diagnosis with expiratory CT. Radiology 2001: 218: 533.
3. Christie JD, Edwards BL, Kucheyavaya YA et al. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant 2012: 31: 1073.
4. Vos R, Vanaudenaerde MB, Verlenden ES et al. Anti-inflammatory and immunomodulatory properties of azithromycin involved in treatment and prevention of chronic lung allograft rejection. Transplantation 2012: 94: 101.
5. Retsema J, Fu W. Macrolides: structures and microbial targets. Int J Antimicrob Agents 2001: 18(Suppl 1): S3.
6. Murphy DM, Forest IA, Corris PA et al. Azithromycin attenuates effects of lipopolysaccharide on lung allograft bronchial epithelial cells. J Heart Lung Transplant 2008: 27: 1210.
7. Ribeiro CM, Hurd H, Wu Y et al. Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia. PLoS ONE 2009: 4: e5806.
8. Vanaudenaerde BM, Wuyts WA, Geudens N et al. Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells. Am J Transplant 2007: 7: 76.
9. Willems-Widyastuti A, Vanaudenaerde BM, Vos R et al. Azithromycin attenuates fibroblast growth factors induced vascular endothelial growth factor via p38(MAPK) signaling in human airway smooth muscle cells. Cell Biochem Biophys 2013: 67: 331.
10. Gerhardt SG, McDyer JF, Girgis RE, Conte JV, Yang SC, Orens JB. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med 2003: 168: 121.
11. Verleden GM, Dupont LJ. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2004: 77: 1465.
12. Yates B, Murphy DM, Forrest IA et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2005: 172: 772.
13. Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2006: 174: 566.
14. Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2008: 85: 36.
15. Porhownik NR, Batobara W, Kepron W, Unruh HW, Bsouty Z. Effect of maintenance azithromycin on established bronchiolitis obliterans syndrome in lung transplant patients. Can Respir J 2008: 15: 199.
16. Shitrit D, Bendayan D, Gidon S, Saute M, Bakal I, Kramer M. Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant 2005: 24: 1440.
17. Vos R, Vanaudenaerde BM, Verlenden SE et al. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J 2011: 37: 164.
18. Vos R, Vanaudenaerde BM, Ottevaere A et al. Long-term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer? J Heart Lung Transplant 2010: 29: 1358.
19. Jain R, Hachem RR, Morrell MR et al. Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome. J Heart Lung Transplant 2010: 29: 531.
20. Verleden SE, Vos R, Mertens V et al. Heterogeneity of chronic lung allograft dysfunction: insights from protein expression in broncho alveolar lavage. J Heart Lung Transplant 2011: 30: 667.
21. Meloni F, Solari N, Morosini M et al. Clinical and immunological evaluation of 12-month azithromycin therapy in chronic lung allograft rejection. Clin Transplant 2011: 000: E381.
22. Kurdowska A, Noble JM, Griffith DE. The effect of azithromycin and clarithromycin on ex vivo interleukin-8 (IL-8) release from whole blood and IL-8 production by human alveolar macrophages. J Antimicrob Chemother 2001: 47: 867.
23. Kanai K, Asano K, Hisamitsu T, Suzaki H. Suppression of matrix metalloproteinase production from nasal fibroblasts by macrolide antibiotics in vitro. Eur Respir J 2004: 23: 671.
24. Tateda K, Comte R, Pechere JC, Kohler T, Yamaguchi K, Van Delden C. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2001: 45: 1930.
25. Yamasawa H, Oshikawa K, Ohno S, Sugiyama Y. Macrolides inhibit epithelial cell-mediated neutrophil survival by modulating granulocyte macrophage colony-stimulating factor release. Am J Respir Cell Mol Biol 2004: 30: 569.
26. Li H, Liu D, Chen L et al. Meta-analysis of the adverse effects of long-term azithromycin use in patients with chronic lung diseases. Antimicrob Agents Chemother 2014: 58: 511.